# NCT06445062 (NCT06445062)

> Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06445062
- Phase: PHASE1, PHASE2
- Status: RECRUITING
- Sponsor: Revolution Medicines, Inc.
- Conditions: Colorectal Cancer; CRC; Pancreatic Ductal Adenocarcinoma; PDAC; Gastrointestinal Cancer; Metastatic Pancreatic Ductal Adenocarcinoma
- Interventions: RMC-6236; mFOLFOX6 regimen; bevacizumab; mFOLFIRINOX regimen; cetuximab; gemcitabine; nab-paclitaxel; RMC-9805; FOLFIRI regimen
- Enrollment: 1130
- Primary outcome: Adverse events (Subprotocols A-F)
- Primary outcome: Dose limiting toxicities (Subprotocols A-F)
- Primary outcome: Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) as assessed by Blinded Independent Central Review (BICR)(Subprotocol G)

## Commentary we found

- X threads: 4

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct06445062